| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cytochrome P450 2C8; EC 1.14.14.1; CYPIIC8; P450 form 1; P450 MP-12/MP-20 |
| Entrez GeneID | 1558; |
| WB Predicted band size | 56kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human Cytochrome P450 2C8. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于 **Cytochrome P450 2C8(CYP2C8)抗体**的参考文献示例(文献信息为虚构示例，仅用于演示格式)：
---
1. **文献名称**: *Development of a Monoclonal Antibody for Specific Detection of CYP2C8 in Human Liver Microsomes*
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种高特异性的单克隆抗体，用于检测人肝微粒体中的CYP2C8蛋白。通过免疫印迹(Western blot)和免疫组化验证，证明该抗体无交叉反应性(如与CYP2C9或CYP3A4)，并成功应用于评估不同个体中CYP2C8的表达水平差异。
2. **文献名称**: *Role of CYP2C8 Genetic Polymorphisms in Drug Metabolism: Insights from Antibody-based Inhibition Assays*
**作者**: Tanaka K, et al.
**摘要**: 利用抗CYP2C8抗体抑制酶活性，结合基因测序技术，揭示了CYP2C8基因多态性(如*CYP2C8*3等位基因)对紫杉醇代谢的影响，为个体化用药提供了实验依据。
3. **文献名称**: *Immunohistochemical Localization of CYP2C8 in Human Hepatocytes and Its Clinical Implications*
**作者**: Lee S, et al.
**摘要**: 通过免疫组化技术，系统分析了CYP2C8在正常及病变肝组织中的分布特征，发现其在非酒精性脂肪肝中的表达显著下调，提示可能与药物代谢能力受损相关。
4. **文献名称**: *A Novel ELISA Method for Quantifying CYP2C8 Protein Levels Using Polyclonal Antibodies*
**作者**: Müller B, et al.
**摘要**: 开发了一种基于多克隆抗体的ELISA检测方法，可定量测定人血浆中CYP2C8的浓度，为临床药物监测及肝功能障碍患者的代谢评估提供了新工具。
---
**注**：以上文献为示例，实际文献需通过PubMed、Web of Science或Google Scholar等平台检索确认。建议使用关键词“CYP2C8 antibody + application/assay/polymorphism”进行精准检索。
Cytochrome P450 2C8 (CYP2C8) is a member of the cytochrome P450 enzyme superfamily, primarily expressed in the liver and involved in the metabolism of numerous endogenous compounds and xenobiotics. It plays a critical role in the oxidative breakdown of drugs, including anticancer agents (e.g., paclitaxel), antidiabetics (e.g., repaglinide), and anti-inflammatory compounds. Genetic polymorphisms in CYP2C8 can lead to interindividual variability in drug metabolism, influencing therapeutic efficacy and toxicity risks.
CYP2C8 antibodies are essential tools for studying the enzyme's expression, localization, and function in both research and clinical settings. These antibodies enable the detection of CYP2C8 protein levels in tissues via techniques like Western blotting, immunohistochemistry, or ELISA. They are also used to investigate drug-drug interactions, genetic variations, and disease-associated alterations in CYP2C8 activity. For instance, reduced CYP2C8 expression has been linked to impaired drug clearance in liver diseases, while overexpression may correlate with resistance to certain therapies.
Clinically, CYP2C8 antibodies aid in pharmacogenomic studies to personalize treatments, particularly for drugs with narrow therapeutic indices. Additionally, they contribute to understanding CYP2C8's role in pathophysiological processes, such as its involvement in arachidonic acid metabolism and potential implications in diabetes, cancer, or cardiovascular disorders. Reliable antibodies with high specificity are crucial for ensuring accurate experimental and diagnostic outcomes.
×
